Top-News

Regenxbio Aktie News

Aktie
WKN:  A140E0 ISIN:  US75901B1070 US-Symbol:  RGNX Branche:  Biotechnologie Land:  USA
13,16 $
+0,18 $
+1,39%
11,302 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
496,10 Mio. €
Streubesitz
7,24%
KGV
-1,73
Index-Zuordnung
-

Regenxbio News

12.05.25 - PR Newswire
REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights
REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights PR Newswire
08.05.25 - PR Newswire
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting PR Newswire
06.05.25 - PR Newswire
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire
30.04.25 - PR Newswire
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights PR Newswire
19.03.25 - PR Newswire
REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY
REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY PR Newswire
13.03.25 - PR Newswire
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates PR Newswire
10.03.25 - PR Newswire
REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference PR Newswire
04.03.25 - PR Newswire
REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases
REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases PR Newswire
26.02.25 - PR Newswire
REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights
REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights PR Newswire
25.02.25 - PR Newswire
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire
09.02.25 - Boersia.de
Regenxbio Aktie: Hintergründe veranschaulicht
Die Regenxbio Inc. verzeichnet aktuell eine interessante Marktposition mit einer Marktkapitalisierung von 393,9 Millionen Euro. Der Aktienkurs liegt derzeit bei 7,95 Euro und konnte ...
02.02.25 - Börse-Global
Regenxbio Aktie: Geschäftszahlen über Erwartungen!
Die Biotechnologie-​Firma Regenxbio steht kurz vor einem wichtigen Meilenstein. Am 6. Februar 2025 wird das Unternehmen auf dem World Symposium zwei bedeutende ...
30.01.25 - PR Newswire
REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025
REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025 PR Newswire
14.01.25 - PR Newswire
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases PR Newswire
13.01.25 - PR Newswire
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program PR Newswire
06.12.24 - PR Newswire
Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »